A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Clinical trial NCT02335411 · COMPLETED
Trial details
- NCT number
- NCT02335411
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-03
- Primary completion
- 2021-07-23
- Enrollment
- 318
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.